After oral administration, nifuroxazide is almost not absorbed in the gastrointestinal tract and has no systemic effect. It acts against sensitive species of bacteria only in the intestine lumen. It is excreted unchanged by the intestine. The rate of elimination depends on the dose of the drug and the gastrointestinal tract motility.
Data on the nifuroxazide interacting with other medications has not been published.
Acute and chronic diarrhea of infectious genesis (without signs of helminthic invasion).
Chronic colitis and enterocolitis.
When treating diarrhea, nifuroxazide treatment should be simultaneously accompanied with oral and intravenous rehydration therapy in accordance with the patient’s condition and the duration of diarrhea.
Alcohol is prohibited during nifuroxazide therapy.
Influence on the ability to drive vehicles and perform work requiring increased concentration of attention and speed of psychomotor reactions.
The drug does not adversely affect the ability to drive vehicles and / or other mechanisms.
- Hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran.
- Deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption.
- Age up to 18 years (for this dosage form).
Capsules of 100 mg and 200 mg. 10 capsules (of 100 mg) or 5, 7, 8 capsules (of 200 mg) are placed in a blister packaging made from a polyvinyl chloride film and aluminum printed lacquered foil. 30 capsules (of 100 mg) or 16, 28 or 30 capsules in a plastic bottle with a screw-on cap or in a polymer can with a screw-on cap. 3 blister packs (for a dosage of 100 mg) or 2 blister packs of 8 capsules each, 4 blister packs of 7 capsules or 6 blister packs of 5 capsules (for a dosage of 200 mg) or 1 bottle or 1 can with the application instruction is placed in a cardboard pack.
Hard gelatin capsules No. 0 are yellow (for a dosage of 100 mg) and capsules No. 00 have yellow bodies and orange caps (for a dosage of 200 mg). The capsules contain yellow granular powder with white patches.
There are no data on adverse effects on the fetus during pregnancy. If necessary, with caution, the drug can be prescribed to pregnant and breastfeeding women.
Store the medication in the place protected from moisture and light at a temperature not higher than 25 ° C. Keep out of the reach of children.
Nitrofuran is an antimicrobial agent. ATH code: A07AH03
- Take inside. Adults: 2 capsules 100 mg each or 1 capsule 200 mg 4 times a day (800 mg / day). Duration of therapy with nifuroxazide - no more than 7 days.
Shelf life is 5 years. Do not use after expiration date
For dosage of 100 mg:
Active component: nifuroxazide 100.0 mg. Excipients: microcrystalline cellulose - 23.0 mg, potato starch - 9.0 mg, magnesium stearate - 4.0 mg, sucrose before the mass of the capsule content 460.0 mg obtianed. Hard gelatin capsules No. 0: 0 [gelatin (up to 100%, water (14-15%), quinoline yellow dye (0.5834%), sunset dye (0.0026%), titanium dioxide (0.9740%) ].
For dosage 200 mg:
Active component: nifuroxazide 200.0 mg. Excipients: microcrystalline cellulose - 58.0 mg, potato starch - 18.0 mg, magnesium stearate - 6.0 mg, sucrose before the mass of the capsule contents 630.0 mg obtained. Hard gelatin capsules No. 00: [gelatin (up to 100%), water (14-15%), Lid: crimson dye [Ponso 4R] (0.079801%), patented blue dye (0.00165%), sunset dye (0.093301%), titanium dioxide (0.813158%); Case: quinoline yellow dye (0.583356%), sunset dye (0.002565%), titanium dioxide (0.974035%)].
The specific symptoms of overdose are not described. Standard emergency measures are recommended.
Over the counter.
A derivative of 5-nitrofuran is a broad spectrum antimicrobial agent used to eliminate infections of the gastrointestinal tract. Nifuroxazide blocks the activity of dehydrogenases and inhibits the respiratory chains, the tricarboxylic acid cycle and other biochemical reactions in the bacterial cell. Destroys the membranes of sensitive bacteria, reduces the production of toxins by microorganisms. Activates immunity, increases the activity of phagocytes and complement titer.
Effective against gram-positive microorganisms:
- Staphylococcus spp.;
- Streptococcus spp.
- Salmonella spp.;
- Klebsiella spp.;
- Enterobacter spp.;
- Escherichia coli;
- Shigella spp.;
- Proteus spp.;
- Haemophilus influenzae;
- Campilobacter spp.;
- Edwarsiella spp.;
- Citrobacter spp.;
- Vibrio cholerae;
- Yersinia enterocolitica.
Nifuroxazide does not affect the state of the normal microflora of the human intestine. In acute bacterial diarrhea, it restores intestinal eubiosis. When the person is infected with enterotropic viruses, it prevents developing bacterial superinfection.